Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7507-7517

  Rose, William C ^a   Lee, Francis Y F ^a   Fairchild, Craig R ^a   Lynch, Mark ^a   Monticello, Thomas ^a   Kramer, Robert A ^a   Manne, Veeraswamy ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIAZEPINES; CATTLE; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RAS PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035886842     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. ras genes
2. Proteins regulating Ras and its relatives
3. The role of p21ras in receptor tyrosine kinase signaling
4. The GTPase superfamily: A conserved switch for diverse cell functions
5. The GTPase superfamily: Conserved structure and molecular mechanism
6. ras GTPase activating protein. Signal transmitter and signal terminator
7. GTP binding and growth control
8. ras oncogenes in human cancer: A review
9. All ras proteins are polyisoprenylated but only some are palmitoylated
10. Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein
11. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation
12. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
13. Ras C-terminal processing enzymes - New drug targets?
14. Inhibitors of Ras farnesyltransferases
15. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
16. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
17. Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design
18. Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase
19. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
20. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
21. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
22. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
23. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
24. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells
25. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells
26. Farnesyltransferase inhibitors versus Ras inhibitors
27. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
28. Activation of the P13′ K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors
29. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
30. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity
31. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
32. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
33. Critical role of Rho in cell transformation by oncogenic Ras
34. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
35. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli
36. Farnesyltransferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
37. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
38. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
39. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
40. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion
41. Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068
42. Farnesyltransferase inhibitors, anti-Ras or anticancer drugs
43. Protein farnesyltransferase as a target for the development of anticancer drugs
44. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
45. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
46. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy
47. Pre-clinical development of farnesyltransferase inhibitors
48. Biological effects and mechanism of action of farnesyltransferase inhibitors
49. The discovery of (R)-7-cyano-2, 3, 4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)- 4-(2-thienylsulfonyl)-1H-1, 4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity
50. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus
51. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis
52. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines
53. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
54. Apoptosis. A basic biological phenomenon with wide-ranging implications in tissue kinetics
55. Quantitation of apoptotic bodies in rat liver by in situ end labeling (ISEL): Correlation with morphology
56. GTP loading of farnesylated p21Ras by insulin at the plasma membrane
57. Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs
58. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells
59. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
60. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation
61. Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A
62. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
63. Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism
64. A farnesyl-protein transferase inhibitor induces p21 expression and Gl block in p53 wild type tumor cells
65. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects
66. K-Ras-independent effects of the farnesyl transferase inhibitor L-744, 832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells
67. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon turnout cells
68. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
69. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
70. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
71. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein
72. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
73. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) α and TGF α/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
74. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
75. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase 1: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine
76. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase BIM-46228
77. A comparison of the therapeutic and preventative efficacy of a novel Ras farnesyltransferase inhibitor in endogenous mouse carcinogenesis models